Company news
Pharmadrug, Inc. news in 2023
Pharmadrug, Inc.'s news releases, calls and decks from 2023, newest first.
PharmaDrug CEO Provides Vision for Securedose Acquisition
December 13, 2023
PharmaDrug Inc. Completes Debt Restructuring
November 15, 2023
PharmaDrug Inc. Announces Grant of Stock Options
November 8, 2023
PharmaDrug Inc. Closes Acqusition of Securedose Synthetics
November 7, 2023
PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
October 27, 2023
PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
October 20, 2023
PharmaDrug Announces Amendment to Shareholder Meeting Matter
September 19, 2023
PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
September 14, 2023
PharmaDrug Announces Appointment of CEO and Changes to the Board of Directors
September 6, 2023
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
July 18, 2023
PharmaDrug Announces Termination of General Security Agreement and Issuance of Common Shares
July 5, 2023
PharmaDrug Brings On Advisor to Maximize Shareholder Value With Its Underlying Assets
May 23, 2023
PharmaDrug Announces Cease Trade Order
May 8, 2023
PharmaDrug Announces Non-Brokered Offering of $100,000 of Convertible Secured Debentures
April 14, 2023
PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch
February 22, 2023
PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer
February 13, 2023
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer
January 31, 2023